| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.0088 | 1 |